Coherent, Zeiss Eye PDT Market Opportunity Pending Visudyne NDA Approval
This article was originally published in The Gray Sheet
Executive Summary
Coherent, Inc. and Zeiss Humphrey Systems are preparing to compete head-to-head for the placement of photodynamic therapy (PDT) lasers to perform "wet" age-related macular degeneration (AMD) therapy in conjunction with QLT PhotoTherapeutics' Visudyne (verteporfin for injection) pending imminent FDA approval for the combined drug/device treatment.
You may also be interested in...
Coherent, Zeiss Supplying Lasers Free For Visudyne Treatment IND Study
Laser manufacturers Coherent and Zeiss are providing their device at no charge to physicians participating in Ciba Vision's treatment IND program for the photodynamic age-related macular degeneration treatment Visudyne (verteprofin).
FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility
The US FDA’s device center has unveiled a new public dataset designed to assist chemistry laboratories in ensuring the robustness of chemical characterization methods used to assess the biocompatibility of medical devices.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.